4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxy-1-(1,4-oxazepan-4-yl)butan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxy-1-(1,4-oxazepan-4-yl)butan-1-one
• 化学式: C₂₈H₃₀FN₃O₅
• 分子量: 507.6
• InChiKey: PBFKDPVBJIAMIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  85.9
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：KALA PHARMACEUTICALS INC

  公开号：WO2014130612A1

  公开（公告）日：2014-08-28

  Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.